Клиническая оценаа химиолучевого лечения лимфомы Ходжкина IIIБ стадии
Диссертация
Лучевое лечение проводилась на гамматерапевтических аппаратах «РОКУС» и линейных ускорителях электронов ЛУЭ-25 и ЛУЭВ-15М1 в тормозном режиме (Ех-15- 27,5 МеВ). Суммарная очаговая доза (СОД) на лимфоколлекторы составляла, как правило, 40 Гр, а на конгломераты лимфатических узлов более 5 см в диаметре — 45−50 Гр. Разовая очаговая доза (РОД) колебалась в пределах 1,8−2,0 Гр. Последовательность… Читать ещё >
Список литературы
- Акимов А.А., Ильин Н. В. Некоторые биологические аспекты лимфомы Ходжкина и новые подходы к ее терапии // Вопр. онкол.-2003.-Т. 49.-С. 31−40.
- Байсоголов Г. Д., Шахтарина С. В. Трехлетние результаты комбинированного лечения больных лимфогранулематозом I-II стдии // Мед. радиол.-1984.-№ 4.-С. 45−60.
- Гершанович M. JL, Канаев С. В., Филатова JI.B. и соавт. Особенности клиники и лечения больных лимфомой Ходжкина с поражением костного мозга //Вопр. онкол.-2002.-Т. 48.-С. 29−36.
- Демина Е.А. Лимфома Ходжкина. Глава в книге: Энциклопедия клинической онкологии: Руководство для практических врачей / М. И. Давыдов, Г. Л. Вышковский и др.- под общ. ред. М. И. Давыдова, Г. Л. Вышковского / -М.: РЛС-2005, 2004.-С. 605−614.
- Ильин Н.В., Коврыжкина Т. А., Акимов А. А. и соавторы Результаты лучевого лечения больных лимфомой Ходжкина II стадии с поражением лимфатических узлов средостения // Вопр. онкол.-2003.-Т. 49.-С. 643 647.
- Ильин Н.В. 7-й международный симпозиум по лимфоме Ходжкина (Кёльн, ноябрь 2007) // Клиническая онкогематология.-2008.-Т. 1, № 1,-С.82−83.
- Канаев С.В., Холин А. В., Гершанович МЛ., Малинин А. П. Прогностические факторы при химиолучевом лечении лимфогранулематоза IIIA стадии // Мед. Радиол. 1988.-№ 7.-С. 40−46.
- Лимфогранулематоз / Под. Ред. Л. П. Симбирцевой и Л. Холсти / -М, Медицина, 1985.
- Ю.Павлов А. С. Лучевая терапия злокачественных опухолей (итоги, проблемы, перспективы). Актовая речь. -ЦОЛИУВ МЗ СССР. -М., 1981.
- П.Павлов В. В., Шахтарина С. В., Багатырева Т. И. и соавторы. Эволюция радиологических подходов в лечении лимфомы Ходжкина I-II стадии (Опыт собственных исследований) // Материалы VIII Российского онкол. конгресса. Москва.-23−25 ноября 2004.-С. 117−118.
- Паныпин Г. А., Сотников В. М., Даценко П. В. и соавторы. Факторы риска и прогнозирование выживаемости при лимфогранулематозе: статистический анализ // Тер. арх,-1991.-№ 7.-С. 36−40.
- Паньшин Г. А., Сотников В. М., Жданов Г. П. и др. Профилактическое облучение легких при лимфогранулематозе // Метод, рекомендации (ред. В.П. Харченко).-М., 1993.
- Паныпин Г. А., Харченко В. П., Сотников В. М. и соавторы. Опыт и перспективы расширенной радикальной программы лучевой терапии с профилактическим облучением легких и печени у больных лимфогранулематозом // Вопр. онкол.-2000.-Т. 46.-С. 718−723.
- Стуков А.Н., Гершанович М. Л., Бланк М. А. и др. Лекарственная терапия опухолей / Под ред. М. Л. Гершановича и В. А. Филова. СПб: NIKA.-2006.-C. 27−35.
- TNM классификация злокачественных опухолей шестое издание/ Под. Ред. проф. Н. Н. Блинова СПб., Эскулап.-2003.-С. 37−61.
- Фридкина Т.В., Кунин П. Е. Результаты лечения и прогноз при лимфогранулематозе // Мед. Радиол.-1972.-№ 17, -С. 9−14.
- Харченко В.П., Панынин Г. А., Сотников В. М., Даценко П. В. Расширенная радикальная программа лучевой терапии с профилактическим облучением легких при лимфогранулематозе // Тер. арх. -1992.-№ 7.-С. 33−36.
- Aleman В.М., Raemaekers J.M., Tirelli U. et al. European Organization for Research and Treatment of Cancer Lymphoma Group: Involved-field radiotherapy for advanced Hodgkin’s lymphoma // N. Engl. J. Med.-2003.-Vol. 348.-P. 2396−2406.
- Andrieu J. M., Colonna P., Desablens B. et al. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for Hodgkin’s disease at advanced stages // Ann. Oncol.-1998.-Vol. 9.-P. 195 203.
- Aviles A., Talavera A., Garcia E.L. et al. La fos-fatafa alcalina como factor pronostico en enfermedad de Hodgkin. (Alkaline phosphatase as a prognostic factor in Hodgkin’s disease) // Rev. Gastroenterol. Mex.-1990.-Vol. 55.-P. 21 l (abstr).
- Biti G, Cellai E, Magrini SM, et al: Second solid tumors and leukemia after treatment for Hodgkin’s disease: An analysat of 1121 pacients from a single institution. Int J Radiat Oncol Biol Phys.-1994.-Vol. 29.-P. 25.
- Brincker H., Bentzen S.M. // Radiotherapy & Oncology.- 1994.-Vol. 30.-P. 227−230.
- Brink A.A., Oudejans J.J., van den Brule A.J. et al. Low p53 and high bcl-2 expression in Reed-Stemberg cells predicts poor clinical outcome for Hodgkin’s disease: involvement of apoptosis resistance? // Mod. Pathol.-1998,-Vol. 11.-P. 376−383.
- Brizel D.M., Winer E.P., Prosnitz L.R. et al. Improved survival in advanced Hodgkin’s disease with the use of combined modality therapy // Int. J. Radiat. Oncol. Biol. Phys.-1990.-Vol. 19-P. 535−542.
- Canellos G.P., Anderson J.R., Propert K.J. et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD // N. Engi. J. Med.-1992.-Vol. 327.-P. 1478−1484.
- Canellos G.P., Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial //N. Engl. J. Med.-2002.-Vol. 346.:P.1417−1418.
- Chronowski G.M., Wilder R.B., Tucker S.L. et al. Beta-2 microglobulin (B2M) is an adverse prognostic factor for overall survival in patients withearly-stage Hodgkin’s disease // Leuk Lymphoma.-2001 .-Vol. 42 (Suppl 2).-P. 82.
- Cimino G., Bid G.P., Anselmo A.P. et al. MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages 1-ПА Hodgkin’s disease // J. Clin Oncol.-1989.-Vol. 7.-P. 732−737.
- Crnkovich M.J., Leopold K., Hoppe R.T., Mauch P.M. Stage I to ПВ Hodgkin’s disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy // J Clin Oncol.-1987.-1989.-Vol. 5.-P. 1041−1049.
- Crowther D., Wagstaff J., Deakin D. et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin’s disease // J. Clin. Oncol.-1984.-Vol. 2.-P. 892−897.
- Dady P.J., McElwain T.J., Austin D.E. et al. Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin’s disease // Br. J. Cancer.-1989.-Vol. 45.-P. 851−859.
- De Vita V.T., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin’s disease // Ann. Intern. Med.-1989.-Vol. 73.-P. 881−895.
- De Vita V.T., Hellman S., Rosenberg S.A. Cancer. Principles and Practice of Oncology. 4-th Edition. Ed. Bu / Philadelphia.-1993.-Vol. 2.
- De Vita V.T., Hellman S., Rosenberg S. A // Cancer. Principles and Practice of Oncology.-Vol. 2.-6 th.-Philadelphia: Lippincott-Raven Pulishers.-2001.-Chapter 45.
- Diehl V, Harris N.L., Mauch P. Hodgkin’s lymphoma/ Cancer 7ed., De Vita V.T., Hellman S., Rosenberg S. A Lippincott Willims & Wilkins.-Philadelphia.-2005.-P. 2020−2075.
- Easson E.S., Russel M.H. The cure of Hodgkin’s disease // Br. Med. J.-1963.-Vol. l.-P. 1704−1707.
- Engers R., Gabbert H.E. Mechanisms of tumor metastasis: cell bio logical aspects and clinical implications // J. Cancer Res. Clin. 0ncol.-2000.-1989.-Vol. 126.-P. 682−692.
- Fabian C.J., Mansfield C.M., Dahlberg S. et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study // Ann. Intern. Med. 1994.-Vol. 120.-P. 903−912.
- Farah R., Ultmann J., Griem M. et al: Extended mantleradiation therapy for pathologic stage I and II Hodgkin’s disease // J. Clin. Oncol. -1988.-Vol. 6.-P. 1047.
- Fischer P., Franlcen T. A multivariate prognosis model for Hodgkin’s disease //Strahlentherapie.-1984.-Vol. 160.-P. 535−542.
- Franklin J. Diehl V. Dose escalated ВЕАСОРР chemotherapy regimen for advanced stage Hodgkin’s disease: final analis of the HD9 randomized trial of the GHSG //Ann. of Oncology.-2002.-Vol. 13, Suppl. 1.-P.-98−101.
- Fuller L.M., Gamble Y.F., Velasquez W.G. et al. Evaluation of the significance of prognostic factors in stage III Hodgkin’s disease treated with MOPP and radiotherapy // Cancer.-1980.-Vol.45.-P. 1352−1364.
- Ganesan T.S., Wrigley P.P., Murray P.A. et al: Radiotherapy for stage I Hodgkin’s disease: 20 years' experience at St. Bartholomew’s Hospital // Br. J. Cancer.-1990.-Vol. 62.-P. 314−318.
- Canellos G.P. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD // N. Engl. J. Med.-1992.-Vol. 327.-P. 1478−1484.
- Gilbert R. Radiotherapy in Hodgkin’s disease (malignant granulomatosis): Anatomic and clinical foundations- governing principles- results // Am. J. Roentgenol.-1939.-Vol. 41.-P. 198−241.
- Gisselbrecht C., Brice P., Lepage E. et al. Autologous bone marrow transplantation in Hodgkin’s disease // Nouv. Rev. Fr. Hematol.-1990.-Vol. 32.-P. 5−7.
- Glatstein E. Radiotherapy in Hodgkin’s disease: past achievements and future progress // Cancer.-1977.-Vol. 36.-P. 837−842.
- Glick J., Tsiatis A., Prosnitz L. et al. Improved survival with sequential Bleo-MOPP followed by ABVD for advanced Hodgkin’s disease (abstract 926) // Proc. Am. Soc. Clin. Oncol.-1984.-Vol. 3.-P. 237.
- Gobbi P.G., Cavalli C., Federico M. et al. Hodgkin’s disease prognosis: a directly predictive equation//Lancet.-1988.-Vol. l.-P. 675−679.
- Gobbi P.G., Cavalli C., Federico M. et al. Increasing interdependency of prognosis-and therapy-related factors in Hodgkin’s disease // Acta. Haematol.-1989.-Vol. 8l.-P. 34−40.
- Gobbi P.G., Ghirardelli M.L., Solcia M. et al. Image-aided estimate of tumor burden in Hodgkin’s disease: evidence of its primary prognostic importance // J. Clin. Oncol.-2001.-Vol. 19.-P. 1388−1394.
- Goodman L.S., Wintrobe M.M., Dameshek W. et al. Nitrogen mustardtherapy//JAMA.-1946.-Vol. 132.-P. 126−132.
- Gospodarowicz M.K., Sutcliffe S.B., Clark R.M. et al. Analysis of supradiaphragmatic clinical stade I and II Hodgkin’s disease treated with radiation alone//Int.J. Radiat.Oncol.Biol.Phys.-1992.-Vol. 22.-P. 859−865.
- Griffin Т., Gerdes A., Parker R. et al. Are pelvic irradiation and routine staging laparotomy necessary in clinical stages IA and IIA Hodgkin’s disease // Cancer.-1977.-Vol. 40.-P. 2914−2916.
- Hagemeister F.B., Fuller L.M., Velasquez W.S. et al. Two cycles of MOPP and radiotherapy: effective treatment for stage III A and IIIB Hodgkin’s disease // Ann. Oncol.-1991 .-Vol. 2.-P. 25.
- Hasencleer D. The disappearanceof progjstic factors in Hodgkin’s disease // Ann. Oncol.-2002.-Vol. 13 (Suppl 1).-P. 75−78.
- Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease // N.Engl. J. Med.-1998.-Vol. 339.-P. 1506−1514.
- Henry-Amar M., Somers R. Survival outcome after Hodgkin’s disease: a report from the international data base on Hodgkin’s disease // Semin. 0ncol.-1990.-vol. 17.-P. 758−768.
- Hellman S., Mauch P. Role of radiation therapy in the treatment of Hodgkin’s disease. Cancer Treatm. Repts.-1982.-Vol. 66.-P. 915−923.
- Hess J.L., Bodis S., Pinkus G. et al. Histopathologic grading of nodularsclerosis Hodgkin’s disease. Lack of prognostic significance in 254 surgically staged patients // Cancer.-1994.-Vol. 74.-P. 708−714.
- Hoppe R.T. Stage I-II Hodgkin’s disease: current therapeutic options and recommendations // Blood.-1982 -Vol. 62, -P. 32−36.
- Hoppe R.T. Hodgkin’s Disease. In: Textbook of Radiation Oncology. Ed. by Leibl S.A. and Phillips T.L., W.B.Saunders Company, Philadelphia.-1998. -P. 1079−1094.
- Hoppe R.T. Hodgkin’s Disease: Second cancer after treatment Hodgkin’s Disease: Complications of therapy and excess mortality // Ann Oncol.-1997.-Vol. 8(Suppl. 1).-P. 115.
- Hoppe R.T., Coleman C.N., Cox R.S. et al: The management of stage I-II Hodgkin’s disease with irradiation alone or combined modality therapy: The Stanford experience // Blood.-1982.-Vol. 59.-P. 455−465.
- Hoppe R.T., Rosenberg S.A., Kaplan H.S., Cox R.S. Prognostic factors in pathological stage ША Hodgkin’s disease // Cancer.-I980.-Vol. 46.-P. 12 401 246.
- Horning S.J., Hoppe R.T., Breslin S. Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin’s Disease: Mature Results of a Prospective Clinical Trial // J Clin Oncol.-2002.-Vol. 20.-P. 630−637.
- Horning S.J., Rosenberg S.A., Hoppe R.T. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease: an update //Ann. Oncol.-1996.-Vol. 7(Suppl 4).-P. 105−108.
- Jerusalem G., Beguin Y., Fassotte M.F. et al. Ann. of Oncol.-2003.-Vol. 14.-P. 123−130.
- Johnson R. E., Thomas L.B., Schneiderman M. et al. Preliminary experience with total nodal irradiation in Hodgkin’s disease // Radiology.-I970.-Vol. 96.-P. 603−608.
- Jones S.E., Haut A., Weick J.K. et al. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin’s disease. A Southwest Oncology Group Study // Cancer.-1983.-Vol. 51.-P. 1339−1347.
- Kaplan E. L, Meier P.: Non-parametric estimation of incomplete observations // J Am Stat Assoc.-1958.-Vol 53.-P. 270−283.
- Kaplan H. S. Hodgkin’s disease // Cambridge et al., -1980.-P.-689.
- Kaplan H. S. On the natural histori, treatment and prognosis of Hodgkin’s disease // Havey Lectures, 1969/-New York.-1970.-P. 215−259.
- Kaplan H. S. The radikal radiotherapy of regionalli lokalized. Hodgkin’s disease//Radiology.-1962.-Vol. 78.-P. 553−561.
- Kaplan H.S., Rosenberg S. Treatment of Hodgkin’s disease // Med. Clin. North. AM.-1966.-Vol. 50.-P. 1591−1610.
- Klimo P., Connors J.M. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease // J Clin Oncol.-1985.-Vol. 3.-P. 1174−1182.
- Kuppers R, Hansmann M.L. The Hodgkin and Reed/Sternberg cell // J. Biochem. Cell. Biol.-2005.-Vol. 37.-P. 511−517.
- Lee C.K., Aeppli D.M., Bloomfield C.D., Levitt S.H. Hodgkin’s disease: A reassessment of prognostic factors following modification of radiotherapy // Int. J. Radiat. Oncol. Biol. Phys.-1987.-Vol. 13.-P. 983−991.
- Leslie N.T., Mauch P.M., Hellman S. Stage IA to ПВ supradiaphragmatic Hodgkin’s disease. Long-tenn survival and relapse frequency // Cancer. -1985.-Vol. 55.-P. 2072−2078.
- Loeffler M., Diehl V, Pfreundschuh M. et al. Journal of Clinical Oncology. -1997,-Vol. 6.-P. 2275−2287.
- Longo D.L., Duffey P.L., De Vita V.T. et al. Treatment of advanced-stage Hodgkin’s disease: alternating non-crossresistant MOPP/CABS is not superior to MOPP//J. Clin. Oncol.-1991.-Vol. 9.-P. 1409−1420.
- Longo D.L., Young R.C., Wesley M. et al. Twenty years of MOPP therapy for Hodgkin’s disease // J. Clin. Oncol.-1986.-Vol. 4.-P. 1295−1306.
- MacLennan K.A., Bennett M.H., Tu A. et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s bdisease. A study of 1659 patients//Cancer.-1989.-Vol. 64.-P. 1686−1693.
- Maltas J., Angus В., Jack F. et al. Improved estimation of tumour burden leads to better prognostic discrimination in classical Hodgkin’s disease in adults // Leuk. Lymphoma.-2001.-Vol. 42. (Suppl 2). -P. 79.
- Mauch P., Armitage J.D., Diehl V. et al. Hodgkin’sdisease.-Philadelphia. -1999.
- Mendenhall N.P. Hodgkin’s Disease In: Clinical Radiation Oncology. Ed. by Gunderson L.L. and Tepper J.E., Churchill Livingstone, N.Y.-2000.-P. 11 161 123.
- Mendenhall N.P., Cantor A.B., Barre D.M. et al: The role of prognostic factors in treatment selection for early-stage Hodgkin’s disease // Am. J. Clin. Oncol.-1994,-Vol. 17.-P. 189.
- Mintz U., Miller J. В., Colomb H. M. Pathologic stage I and II Hodgkin’s disease, 1968−1975. Relapses and results of retreatment. Cancer, 1979, -Vol. 66.-P. 799−803.
- Nadali G., Tavecchia L., Zanolin E. et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcome // Blood.-1998.-Vol. 91.-P. 3011−3016.
- Nadali G., Vinante F., Ambrosetti A. et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis // J. Clin. Oncol.-1994.-Vol. 12.-P. 793−797.
- Peters M.V. A study of survivals in Hodgkin’s disease treated radiologically // Am. J. Roentgenol.-1950.-Vol. 63.-P. 299−311.
- Peters M.V., Middemiss K.C.H. A study of Hodgkin’s disease treated radiologically//Am. J. Roentgenol.-1958.-Vol. 79.-P. 114−121.
- Pusey W. A. Cases of sarcoma and of Hodgkin’s disease treated by exposure of X-rays // J. Am. Med. Ass.-1902.-Vol. 38.-P.166−169.
- Ranson M.R., Radford J.A., Swindell R. et al. An analysis of prognostic factors in stage ITI and IV Hodgkin’s disease treated at a single centre with MVPP //Ann. Oncol.-1991.-Vol. 2.-P. 423−429.
- Rassidakis G.Z., Medeiros L.J., Nadali G. et al. BCL-2 expression in Hodgkin/Reed-Sternberg cells UHRS: prognostic significance in Hodgkin’s disease (HD) patients // Leuk. Lymphoma.-2001.-Vol. 42(Suppl 2).-P. 83.
- Rock D.B., Schultz C.J., Murray K.J. et al: Continuous split course irradiation f r stage I and II Hodgkin’s disease: 20 year experience at the Medical College of Wisconsin// Radiother. Oncol.-1994.-Vol. 30.-P. 222.
- Rodgers R.W., Fuller L.M., Hagemeister F.B. et al. Reassessment of prognostic factors in stage IIIA and UIB Hodgkin’s disease treated with MOPP and radiotherapy // Cancer.-1981.-Vol. 47.-P. 2196−2203.
- Santoro A., Bonadonna G., Bonfante V., Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin’s disease // N. Engl. J. Med.-1982.-Vol. 306.-P. 770−775.
- Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease // Ann. Intern. Med.-1982.-Vol. 96.-P. 139−143.
- Selby P., Patel P., Milan S. et al. ChlVPP combination chemotherapy for Hodgkin’s disease: long-term results // Br. J. Cancer.-I990.-Vol. 62.-P. 279 285.
- Sieber M., Engert A., Diehl V // Ann. Oncol.-2000.-Vol. 1 l (Suppl 1).-P. 81−85.
- Smolewski P., Niewiadomska H., Los E., Robak T. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells- clinical and pathological implications in patients with Hodgkin’s disease // Int. J. Oncol.-2000.-Vol. 17.-P. 603−609.
- Specht L., Hasenclever D. Prognostic factors of Hodgkin’s Disease. In: Mauch, Armitage, Diehl, Hoppe and Meiss. Hodgkin’s Disease, 1999, Lippincott Willims & Wilkins, Philadelphia.-P. 295−325.
- Specht L., Nissen N. Prognostic factors in Hodgkin’s disease stage IV // Eur. J. Haematol.-1988.-Vol. 41.-P. 359−367.
- Specht L., Nissen N. Prognostic significance of tumour burden in Hodgkin’s disease PS I and II // Scand. J. Haematol.-1986.-Vol. 36.-P. 367 375.
- Specht L., Nissen N.I. Prognostic factors in Hodgkin’s disease stage HI with special reference to tumour burden // Eur. J. Haematol.-1988.-Vol. 41.-P. 80−87.
- Specht L. Hodgkin’s disease. In: Prognostic Factors in Cancer, end.ed. Ed. by. Gospodarowicz M.K. et al.(UICC), Wiley-Liss, N.Y.-2001-P. 673 687.
- Specht L. Prognostic factors in early stage Hodgkin’s disease // Leuk. Lymphoma.-2001.-Vol. 42 (Suppl 2).-P. 9.
- Specht L. Tumour burden as the main indicator of prognosis in Hodgkin’s disease // Eur. J. Cancer.-1992.-Vol. 28A.-P. 1982−1985.
- Stein H., Delson G., Pileri S. Et al. Hodgkin lymphoma. In: Patology and gehetics of tumors of haematopoietic and lymphoid tissues Ed. By Jaffe E.S., Harris N.S., Stein H., Vardiman J.W., IARC Press, Lyon.-2001.-P. 237−253.
- Sutcliffe S.B., Gospodarowicz M.K., Bergsagel D.E. et al. Prognostic groups for management of localized Hodgkin’s disease // J. Clin. Oncol.-1985.-Vol. 3.-P. 393−401.
- Sutcliffe S.B., Wrigley R.F., Peto J. et al. MVPP chemotherapy regimen for advanced Hodgkin’s disease // Br. Med. J.-1978.-Vol. l.-P. 679−683.
- Sweetenhan J.W., Hodgkin’s disease in adults. In: Oxford Textbook of Oncology. 2th ed. // Ed. by Souhami R.L., Tannock I., Hohenberger P. and Horiot J. C" Oxford.-2002.-P. 2283−2323.
- Swerdlow A.J. Epidemiology of Hodgkin’s disease and non-Hodgkin's lymphoma // Eur. J. Nucl. Med. Mol. Imaging.-2003.-Vol. 30 (Suppl. 1). -P. 3−12.
- Thomas R.K., Re D., Wolf J., Diehl V. Part I. Hodgkin’s lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells // Lancet. Oncol.-2004.-Vol. 5.-P. 1 1−18.
- Tubiana M., Henry-Amar M., Hayat M. et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease // Cancer.-1984,-Vol. 54.-P. 885−894.
- Tubiana M., Henry-Amar M., Werf-Messing B. et al. A multivariate analysis of prognostic factors in early stage Hodgkin’s disease // Int. J. Radiat. Oncol. Biol. Phys.-1985.-Vol. 1 l.-P. 23−30.
- Vassilakopoulos T.P., Nadali G., Angelopoulou M.K. et al. The prognostic significance of pVmicroglobulin in Hodgkin’s lymphoma // Leuk. Lymphoma.-2001.-Vol. 42(Suppl 2).-P. 83.
- Vijayakumar S., Myrianthopoulos L.C. An update dose-response analysis in Hodgkin’s disease. Radiother.Oncol.-1992.-Vol. 24.-P. 1−13.
- Viviani S., Bonadonna G., Santoro A. et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results//J. Clin. Oncol.-1996.-Vol. 14.-P. 1421−1430.
- Wagstaff J., Steward W., Jones M. et al. Factors affecting remission and survival in patients with advanced Hodgkin’s disease treated with MVPP // Hematol. Oncol.-1986.-Vol. 4.-P. 135−147.
- Wagstaff J., Gregory W.M., Swindell R. et al. Prognostic factors for survival in stage IIIB and IV Hodgkin’s disease: a multivariate analysis comparing two specialist centres // Br. J. Cancer.-1988.-Vol. 58.-P. 487.
- Wiernik P.H., Gustafson J., Schimpff S.C., Diggc Ch. Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Recults eight years later//Am. J. Med.-1979.-Vol. 67.-P. 183−193.
- Wolf J., Diehl V. Hodgkin’s disease -pathogenesis and therapy // Ther. Umsch.-1996.-Vol. 53.-P. 140−146.
- Yelle L., Bergsagel D., Basco V. et al. Combined modality therapy of Hodgkin’s disease: 10-year results of National Cancer Institute of Canada
- Clinical Trials Group multicenter clinical trial // J Clin Oncol.-1998.-Vol. 9.-P. 1983.
- Zander Т., Wiedenmann S., Wolf J. Prognostic factors Hodgkin’s lymphoma//Ann. Oncol.-2002.-Vol. 13 (Suppl).-P. 67−74.
- Zittoun R., Audebert A., Hoermani B. Et al. // J. Clin. Oncol.-1985.-Vol. 3.-P. 203−214.